Prognostic significance of the peripheral blood absolute monocyte count in patients with locally advanced or metastatic hepatocellular carcinoma receiving systemic chemotherapy

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 15, 2014, Pages 6387-6390

  Lin, Gui Nan ^a   Jiang, Xiao Mei ^a   Peng, Jie Wen ^a   Xiao, Jian jun ^a   Liu, Dong Ying ^a   Xia, Zhong Jun ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; BLOOD; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW UP; HUMAN; LIVER NEOPLASMS; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MONOCYTE; MORTALITY; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MONOCYTES; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 84944276795     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.15.6387     Document Type: Article

References (33)

1. Benetti A, Berenzi A, Gambarotti M, et al (2008). Transforming growth factor-beta1 and CD105 promote the migration of hepatocellular carcinoma-derived endothelium. Cancer Res, 68, 8626-34.
2. Castello G, Scala S, Palmieri G, et al (2010). HCV-related hepatocellular carcinoma: From chronic inflammation to cancer. Clin Immunol, 134, 237-50.
3. Chen J, Li G, Meng H, et al (2012). Up regulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas. Cancer Immunol Immunother, 61, 101-8.
4. Cheng AL, Kang YK, Chen Z, et al (2009). Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol, 10, 25-34.
5. Cui L, Liu XX, Jiang Y, et al (2012). Comparative study on transcatheter arterial chemoembolization, portal vein embolization and high intensity focused ultrasound sequential therapy for patients. Asian Pac J Cancer Prev,13, 6257-61.
6. Dai J, Tang K, Xiao W, et al (2014). Prognostic significance of C-reactive protein in urological cancers: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 15, 3369-75.
7. Farazi PA and DePinho RA (2006). Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer, 6, 674-87.
8. Gao J, Xie L, Yang WS, et al (2012). Risk factors of hepatocellular carcinoma-current status and perspectives. Asian Pac J Cancer Prev, 13, 743-52.
9. Gomaa AI, Hashim MS, Waked I (2014). Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt. PLoS One, 9, e90929.
10. He SL, Shen J, Sun XJ, et al (2013). Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments. World J Gastroenterol, 19, 4552-8.
11. Huang JJ, Li YJ, Xia Y, et al (2013). Prognostic significance of peripheral monocyte count in patients with extranodal natural killer/T-cell lymphoma. BMC Cancer, 13, 222.
12. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
13. Kuang DM, Peng C, Zhao Q, et al (2010). Tumor-activated monocytes promote expansion of IL-17-producing CD8+ T cells in hepatocellular carcinoma patients. J Immunol, 185, 1544-9.
14. Lee YY, Choi CH, Sung CO, et al (2012). Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: comparison with SCC-Ag level. Gynecol Oncol, 124, 92-7.
15. Li J, Jiang R, Liu WS, et al (2013). A large cohort study reveals the association of elevated peripheral blood lymphocyte-tomonocyte ratio with favorable prognosis in nasopharyngeal carcinoma. PLoS One, 8, e83069.
16. Liu H, Pan Z, Li A, et al (2008). Roles of chemokine receptor 4 (CXCR4) and chemokine ligand 12 (CXCL12) in metastasis of hepatocellular carcinoma cells. Cell Mol Immunol, 5, 373-8.
17. Lok AS, Seeff LB, Morgan TR, et al (2009). Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology, 136, 138-48.
18. Louafi S, Boige V, Ducreux M, et al (2007). Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer, 109, 1384-90.
19. Ma WJ, Wang HY and Teng LS (2013). Correlation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis of hepatocellular carcinoma (HCC) after hepatectomy. World J Surg Oncol, 11, 212.
20. Ma TC, Shao HB, Xu Y, et al (2013). Three treatment methods via the hepatic artery for hepatocellular carcinoma-a retrospective study. Asian Pac J Cancer Prev, 14, 2491-4.
21. Norsa'adah B, Nurhazalini-Zayani CG (2013). Epidemiology and survival of hepatocellular carcinoma in north-east Peninsular Malaysia. Asian Pac J Cancer Prev, 14, 6955-9.
22. Peng SH, Deng H, Yang JF, et al (2005). Significance and relationship between infiltrating inflammatory cell and tumor angiogenesis in hepatocellular carcinoma tissues. World J Gastroenterol, 11, 6521-4.
23. Qin S, Bai Y, Lim HY, et al (2013). Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol, 31, 3501-8.
24. Sasaki A, Iwashita Y, Shibata K, et al (2006). Prognostic value of preoperative peripheral blood monocyte count in patients with hepatocellular carcinoma. Surgery, 139, 755-64.
25. Schimanski CC, Bahre R, Gockel I, et al (2006). Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4. Br J Cancer, 95, 210-7.
26. Takai H, Kato A, Kato C, et al (2009). The expression profile of glypican-3 and its relation to macrophage population in human hepatocellular carcinoma. Liver Int, 29, 1056-64.
27. Wang Z, Wu XL, Zeng WZ et al (2013). Meta-analysis of the efficacy of sorafenib for hepatocellular carcinoma. Asian Pac J Cancer Prev, 14, 691-4.
28. Werno C, Menrad H, Weigert A, et al (2010). Knockout of HIF-1a in tumor-associated macrophages enhances M2 polarization and attenuates their pro-angiogenic responses. Carcinogenesis, 31, 1863-72.
29. Yang HI, Lu SN, Liaw YF, et al (2002). Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med, 347, 168-74.
30. Yang Y, Nagano H, Ota H, et al (2007). Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery, 141, 196-202.
31. Yu Q, Yu XF, Zhang SD, et al (2013). Prognostic role of C-reactive protein in gastric cancer: a meta-analysis. Asian Pac J Cancer Prev, 14, 5735-40.
32. Zheng YB, Zhao W, Liu B, et al (2013). The blood neutrophil-tolymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib. Asian Pac J Cancer Prev, 14, 5527-31.
33. Zhu XD, Zhang JB, Zhuang PY, et al (2008). High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol, 26, 2707-16.